Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 12Neoplasms 5Myelodysplastic Syndromes 5Carcinoma, Non-Small-Cell Lung 4Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 3Urinary Bladder Neoplasms 2Recurrence 2Pathologic Complete Response 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Lung Neoplasms 2Hodgkin Disease 2Breast Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1

Interventions

venetoclax 1olutasidenib 1magrolimab 1fludarabine 1cc-486 1Mitoxantrone 1Etoposide 1Dexamethasone 1Decitabine 1Cytarabine 1Cyclophosphamide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myeloid Malignancies × cc-486 × Clear all
NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Gilead Sciences

Phase 2 Terminated
54 enrolled 26 charts

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡